Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-LeY-CAR-transduced autologous T lymphocytes

Genetically modified, autologous T lymphocytes transduced with a retroviral vector encoding a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) Lewis-Y (LeY), with potential immunomodulating and antineoplastic activities. Upon intravenous administration, anti-LeY-CAR-transduced autologous T lymphocytes specifically target and induce selective toxicity in LeY-expressing tumor cells. LeY, a difucosylated carbohydrate antigen, is overexpressed by a variety of cancer cell types.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	autologous-derived LeY-targeted CAR-T cells LeY-targeted autologous CAR-T cells LeY-targeted CAR-T cells

anti-LeY-CAR-transduced autologous T lymphocytes

Search NCI's Drug Dictionary